Physician profile
Edress Othman
NPI 1508916792
$856.48
in general payments reported to CMS, 2019-2025
16 companies · $22.05 in 2025
The $22.05 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2021: $29.26 · 2022: $163 · 2023: $279 · 2024: $115 · 2025: $22.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $137.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $134.28 | 2019-2023 | Epanova |
| Celgene Corporation | $111.96 | 2023-2025 | Reblozyl, Pomalyst |
| Myriad Genetic Laboratories, INC. | $72.67 | 2023-2024 | Myrisk, Mychoice Cdx |
| Daiichi Sankyo INC. | $71.60 | 2022 | |
| Glaxosmithkline, LLC. | $58.21 | 2021-2023 | Jemperli, Zejula |
| Seagen INC. | $48.98 | 2022-2023 | Padcev |
| Merck Sharp & Dohme LLC | $45.71 | 2023-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $45.16 | 2021-2022 | |
| Foundation Medicine, INC. | $29.13 | 2023 | Foundationone Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $28.18 | 2023 | Ninlaro |
| Sumitomo Pharma America, INC. | $17.12 | 2023 | Orgovyx |
| Karyopharm Therapeutics INC. | $14.54 | 2023 | Xpovio |
| Morphosys, US INC. | $14.12 | 2023 | Monjuvi |
| Myovant Sciences INC. | $13.94 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $12.89 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edress Othman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.